EIT KIC 2022

2022 年 EIT 创智中心

• 批准号: 10052341
• 金额: $ 28.58万
• 依托单位: IMPERIAL COLLEGE LONDON
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10052341
• 关键词: EIT; KIC; 2022

The IMPACCT study will investigate whether it is possible to use a new diagnostic test to identify and classify patients with sepsis who are at higher risk of poor outcomes and developing new infections. The IMPACCT study is being sponsored and managed by Imperial College London in the UK and the Chief Investigator is Professor Anthony Gordon. Sepsis is when severe infection leads to organ failure. It is a major global healthcare problem. Recent studies suggest as many as 49 million cases of sepsis worldwide each year leading to 11 million deaths. As sepsis care has improved more patients now recover from the early phases of sepsis but repeat occurrences are a major problem. Patients with sepsis often experience weakening of their immune systems known as immune suppression. This is now recognised as an important feature in a large proportion of patients who have sepsis and it leads to poor outcomes for these patients. At present there is no clinical test to assess the immune function of patients who have sepsis. IMPACCT will evaluate if a rapid RNA-based diagnostic test that produces an Immune Profiling Panel (IPP) can identify patients with sepsis who are immunosuppressed and at higher risk of poor outcomes. It is an observational study with no intervention or novel treatment introduced and no change to patients’ standard care and treatment when taking part. Over a 2-year period, the study will recruit 600 patients in hospitals in the UK, France, and Sweden.Participants will be adult patients in intensive care who are being, or have been, treated for suspected sepsis and are receiving, or have received, organ support. The patients will have been admitted to an ICU for over 48hours and less than 120 hours (5 days) and are expected to require ongoing care in an environment capable of providing organ support for at least one more calendar day. The study research team will collect data on the patient’s medical condition throughout their treatment in hospital and will conduct a clinical diagnostic test on participants’ blood samples. Blood samples will be taken from patients at 3 time points during the study and will be taken from indwelling lines where present. Test results will not be shared with the research team or influence patients’ care. Patients will be contacted 90 days after inclusion to complete a diary regarding their wellbeing and any new infections.

IMPACCT研究将调查是否有可能使用一种新的诊断测试来识别和分类败血症患者，这些患者具有较高的预后不良和发展为新感染的风险。这项IMPACCT研究由英国伦敦帝国理工学院赞助和管理，首席调查员是安东尼·戈登教授。脓毒症是指严重感染导致器官衰竭。这是一个重大的全球医疗保健问题。最近的研究表明，全世界每年有多达4900万例脓毒症病例，导致1100万人死亡。随着脓毒症护理的改善，现在有更多的患者从脓毒症的早期阶段恢复过来，但重复发生是一个主要问题。脓毒症患者通常会经历他们的免疫系统减弱，即免疫抑制。现在，这被认为是很大一部分脓毒症患者的重要特征，并导致这些患者的预后较差。目前还没有临床试验来评估脓毒症患者的免疫功能。IMPACCT将评估一种基于RNA的快速诊断测试是否可以产生免疫特征分析小组(IPP)来识别免疫抑制和预后不良风险较高的脓毒症患者。这是一项观察性研究，参与时不会引入干预或新的治疗方法，也不会改变患者的标准护理和治疗。在两年的时间里，这项研究将在英国、法国和瑞典的医院招募600名患者。参与者将是正在接受或已经接受疑似脓毒症治疗并正在接受或已经接受器官支持的重症监护的成年患者。这些患者将在ICU入院超过48小时但不到120小时(5天)，预计需要在能够提供至少一天多器官支持的环境中持续护理。研究研究小组将收集患者在医院接受治疗期间的健康状况数据，并对参与者的血液样本进行临床诊断测试。血液样本将在研究过程中的3个时间点从患者身上采集，并将在有留置管路的地方采集。检测结果不会与研究团队分享，也不会影响患者的护理。患者将在纳入90天后被联系，以完成关于他们的健康状况和任何新感染的日记。